Citation Impact
Citing Papers
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
2009 Standout
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy
2017
Tissue confirmation of disease recurrence in breast cancer patients: Pooled analysis of multi-centre, multi-disciplinary prospective studies
2011
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Breast cancer assessment tools and optimizing adjuvant therapy
2010
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
2014
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
2022 Standout
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases
2013
Breast cancer
2019 Standout
HER2 status in a population-derived breast cancer cohort: discordances during tumor progression
2010
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes
2009
Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis
2011
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
2012
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells
2013
Src: a potential target for the treatment of triple-negative breast cancer
2011
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
2013
WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial
2013
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
Genetic Predisposition Directs Breast Cancer Phenotype by Dictating Progenitor Cell Fate
2011
Personalized treatment of early-stage breast cancer: Present concepts and future directions
2010
Breast cancer
2016 Standout
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
High level PHGDH expression in breast is predominantly associated with keratin 5‐positive cell lineage independently of malignancy
2015
Wnt signaling in cancer
2016 Standout
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
2020 Standout
WNT signalling pathways as therapeutic targets in cancer
2012 Standout
Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow
2013
Modulation of oxidative stress as an anticancer strategy
2013 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
A clinically relevant gene signature in triple negative and basal-like breast cancer
2011
Tumour heterogeneity in the clinic
2013 Nature
Triple negative breast cancer - prognostic factors and survival
2011
FZD7 has a critical role in cell proliferation in triple negative breast cancer
2011
Metazoan MicroRNAs
2018 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Gene signatures of breast cancer progression and metastasis
2011
Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo
2017
Prognostic value of chemotherapy-induced neutropenia in early-stage breast cancer
2011
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
2013 StandoutNobel
Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
2017
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
Neutrophils in cancer: neutral no more
2016 Standout
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
2013
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
ROS and the DNA damage response in cancer
2018 Standout
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Serine Synthesis Helps Hypoxic Cancer Stem Cells Regulate Redox
2016 StandoutNobel
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Androgen Receptor, EGFR, and BRCA1 as Biomarkers in Triple-Negative Breast Cancer: A Meta-Analysis
2015
Hypoxia-inducible factors regulate pluripotency factor expression by ZNF217- and ALKBH5-mediated modulation of RNA methylation in breast cancer cells
2016 StandoutNobel
Breast Cancer Treatment
2019 Standout
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
2011
Works of C Liedtke being referenced
Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer
2009
Abstract S1-7: Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study.
2012
Triple-negative breast cancer—current status and future directions
2009
WSG PLAN B trial: Evaluating efficacy of anthracycline-free chemotherapy in primary HER2-negative breast cancer after molecular-based risk assessment according to Oncotype DX and uPA/PAI-1.
2010
Abstract S5-5: Identification of a Clinically Relevant Gene Signature in Triple Negative and Basal-Like Breast Cancer
2010
Predictive biomarkers for preoperative endocrine therapy of stage II-III breast cancer by tissue microarrays
2008
Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.
2011
S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.
2011
Secreted Frizzled Receptor Protein 1 (sFRP-1) as Both a Potential Novel Biomarker of Triple Negative Breast Cancer (TNBC), and Its Sensitivity Against Taxane/Anthracycline Containing Neoadjuvant Chemotherapy.
2009